Limitations of inferences from observational databases in amyotrophic lateral sclerosis: All that glitters is not gold

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 3, Issue 3, 2002, Pages 109-112

  Armon, Carmel ^a   Guiloff, Roberto J ^b   Bedlack, Richard ^c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Neuromuscular Unit   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Databases; MOtor neurone disease; Riluzole

Indexed keywords

ALTEPLASE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL; VITAL CAPACITY;

AMYOTROPHIC LATERAL SCLEROSIS; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RILUZOLE; TREATMENT OUTCOME;

EID: 0036762085     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/146608202760834094     Document Type: Review

References (19)

1. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. The King's database 1990-2000: An analysis of the effect on survival of interventions in (Abstract) ALS 2001; 2 (Suppl. 2): 43.
2. Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardiman O. Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000 (Abstract). ALS 2001; 2 (Suppl. 2): 43-44.
3. Brooks BR, Belden DS, Roelke K, et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - motor neuron disease (MND) patients with disease onset before and since 1996 is identical: A clinic-based epidemiologic study (Abstract) ALS 2001; 2 (Suppl. 2): 60-61.
4. Bensimon G, Lacomblez L, Meininger V (ALS/Riluzole Study Group). A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis (Amyotrophic Lateral Sclerosis/Riluzole Study Group II). Lancet 1996; 347: 1425-1431.
6. Cuiloff RJ, Goonetilleke A, Emami J. Riluzole and amyotrophic lateral sclerosis (Letter). Lancet 1996; 348: 336-337.
7. Sandercock J, Burls A, Hyde C, Fry-Smith A, Barton P, Bryan S, Stewart A. Riluzole for motor neurone disease. More trials are needed (Letter). BMJ 2001; 322: 1305.
8. Wheatley K, Gray R. Riluzole for motor neurone disease. Large, more economical trial is needed (Letter). BMJ 2001; 322: 1305.
9. Johnson RT. Reporting clinical trials: full access to all the data. Ann Neurol 2002; 51: 2-3.
10. Byar DP. Problems with using observational databases to compare treatments. Stat Med 1991; 10: 663-666.
11. Moses LE. Measuring effects without randomized trials? Options, problems, challenges. Med Care 1995: 33 (Suppl 4); AS8-14.
12. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? (Editorial). N Engl J Med 2000; 342: 1907-1909.
13. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
14. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
15. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-830.
16. Colditz CA, Miller JN, Mosteller F. How study design affects outcomes in comparisions of therapy: I. Medical. Stat Med 1989; 8: 441-454.
17. Kresowik TF, Hemann RA, Crund SL, et al. Improving the outcomes of carotid endarterectomy: results of a statewide quality improvement project. J Vasc Surg 2000; 31: 918-926.
18. Irish WD, Macdonald DR, Cairncross JG. Measuring bias in uncontrolled brain tumor trials - to randomize or not to randomize? Can J Neurol Sci 1997; 24: 307-312.
19. Armon C, Graves MC, Moses D, Forté DK, Sepulveda L, Darby SM, Smith RA. Linear estimates of rate of disease progression predict survival in patients with ALS. Muscle Nerve 2000; 23: 874-882.